Register now
Register to receive full, unrestricted access to our resources, regular updates and partnership opportunities
This page is intended for UK healthcare professionals and other relevant decision makers only. If you are a member of the public, please click here.
This portal is funded and owned by Novartis Pharmaceuticals UK Ltd and includes content approved by Novartis.
Adverse events reporting information can be found in the footer of this page.
This podcast explores how collaborative working projects (CWPs) between the pharmaceutical industry and the NHS can be successfully developed and delivered to improve patient outcomes and support healthcare system efficiency.
Hosted by John Bingham from The Clarion Portfolio, the session features expert insight from Jeremy Dixon, Value & Access Marketing Director and Helen Fotheringham, Solution & Service Design Lead, at Novartis UK. Together, they provide a practical overview of what CWPs involve, why they are important to the healthcare system, and how to navigate the process of setting one up.
The discussion covers key requirements, governance considerations, and best practices for building effective partnerships, offering clear guidance for teams looking to unlock the value of true collaboration.
Explore the key steps to compliant, transparent and successful collaborative working, from project scoping to completion and outcomes, that aims to deliver a win for all: patients, the NHS and industry.
This episode is part of our series exploring the impact of collaborative working in the UK. Discover the other episodes in the series below and hear more about these innovative partnerships in action.
Discover how partnership-led change between the pharmaceutical industry and the NHS is shaping the future of healthcare.
UK | June 2026 | FA-11644695 Fictional patient and healthcare professional images.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.